FORA Capital’s Vertex Pharmaceuticals VRTX Stock Holding History

FORA Capital’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-3,168	Closed	-$1.24M	–	665
2025 Q3	$1.24M	Buy	+3,168	New	+$1.32M	0.22%	122
2024 Q4	–	Sell	-9,402	Closed	-$4.37M	–	610
2024 Q3	$4.37M	Buy	9,402 +1,229	+15%	+$590K	0.51%	54
2024 Q2	$3.83M	Buy	8,173 +3,329	+69%	+$1.44M	0.47%	70
2024 Q1	$2.02M	Buy	+4,844	New	+$2.05M	0.17%	162
2023 Q4	–	Sell	-15,189	Closed	-$5.28M	–	658
2023 Q3	$5.28M	Buy	15,189 +11,257	+286%	+$3.94M	0.46%	56
2023 Q2	$1.38M	Buy	+3,932	New	+$1.32M	0.2%	134
2022 Q1	–	Sell	-5,909	Closed	-$1.3M	–	642
2021 Q4	$1.3M	Sell	5,909 -17	-0.3%	-$3.31K	0.5%	49
2021 Q3	$1.07M	Buy	+5,926	New	+$1.16M	0.27%	111
2021 Q2	–	Sell	-4,157	Closed	-$893K	–	1169
2021 Q1	$893K	Buy	+4,157	New	+$913K	0.29%	71
2020 Q2	–	Sell	-3,741	Closed	-$890K	–	1344
2020 Q1	$890K	Sell	3,741 -8,253	-69%	-$1.89M	0.19%	142
2019 Q4	$2.63M	Buy	+11,994	New	+$2.43M	0.26%	87

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

FORA Capital's VRTX Position: Q4 2025 in Review

FORA Capital sold out of Vertex Pharmaceuticals (VRTX) in Q4 2025, closing a stake of 3,168 shares — an estimated $1.24M sold.

FORA Capital first reported a position in VRTX in Q4 2019 and held it in 11 quarters. The position peaked at $5.28M in Q3 2023. 1,668 funds tracked by Wall St. Rank hold VRTX as of Q4 2025.

FORA Capital reported no remaining Vertex Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
FORA Capital sold 3,168 Vertex Pharmaceuticals shares in Q4 2025, an estimated $1.24M.
FORA Capital first reported a position in Vertex Pharmaceuticals in Q4 2019 and held it in 11 quarters.
FORA Capital's Vertex Pharmaceuticals position peaked at $5.28M in Q3 2023.
1,668 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2025.

Based on FORA Capital's 13F filing for Q4 2025, filed 13 Feb 2026.